8-K: Lifeloc Q2 Revenue Declines, Focuses on SpinDx Drug Testing

Lifeloc Technologies reported a 7% decline in second-quarter 2025 net revenue and an increased net loss, while continuing significant investment in its SpinDx drug testing platform.

Summary

• Net revenue for the second quarter of 2025 was $2.219 million, a 7% decrease compared to $2.387 million in the second quarter of 2024.
• A net loss of $(394) thousand, or $(0.14) per diluted share, was reported for Q2 2025, compared to a net loss of $(298) thousand, or $(0.12) per diluted share, in Q2 2024.
• For the first six months of 2025, net revenues were $4.496 million, with a net loss of $(686) thousand, or $(0.25) per diluted share.
• This compares to net revenues of $4.541 million and a net loss of $(582) thousand, or $(0.24) per diluted share, for the same six months of 2024.
• Total gross margin remained stable at 41.7% in Q2 2025 (vs. 41.6% in Q2 2024) and 40.8% for the first six months of 2025 (vs. 40.3% in 2024), with price increases largely offsetting inflation and tariff costs.
• Research and development investment remained high at $623 thousand for the quarter, primarily for SpinDx development, contributing to the current period loss.
• Cash and cash equivalents decreased to $995,750 as of June 30, 2025, from $1,243,746 at December 31, 2024.

Sentiment

Score: 4

Explanation: The company reported declining revenue and increased losses, and indicated a potential need for additional financing. However, it is making significant R&D progress on its SpinDx drug testing platform, which is identified as a major growth opportunity and could be transformative if successful. The stable gross margin and strategic focus on a high-growth market provide some balance to the negative financial performance.

Positives

• The core alcohol detection product line, including L-series LX9 and LT7 units, is strong, driving market penetration by meeting previously unaddressable market needs.
• L-series devices have been certified to meet modern registration standards, such as SAIs (Standards Australia International) latest AS 3547:2019 standards for Breath Alcohol Detectors.
• FC-series devices remain popular with many law enforcement and international organizations.
• The Easycal automated calibration station, the only automated calibration available for portable breath alcohol testers, builds valuable protection around the brand and contributes to market share gains.
• Significant progress has been made in leveraging the SpinDx technology platform for rapid detection of drugs of abuse, with laboratory demonstrations showing effective detection of delta-9-THC, cocaine, fentanyl, amphetamine, methamphetamine, morphine, MDMA, and benzodiazepines.
• SpinDx measurement technology has been validated against the definitive standard liquid chromatography-mass spectroscopy (LCMS) measurement utilizing human samples, with test results on real-world human saliva tests at a limit of detection of approximately 10 ng/ml.
• Beta testing of the SpinDx oral fluid testing system utilizing delta-9-THC only tests with a prototype reader has begun.
• Approved for trading on the OTCID, the new market tier of the OTC Markets, commencing July 1, 2025, which may create greater market confidence and allow a more liquid marketplace for shareholders.

Negatives

• Net revenue declined by 7% in the second quarter of 2025 compared to the same period last year.
• Net loss increased to $(394) thousand in Q2 2025 from $(298) thousand in Q2 2024.
• The six-month net loss increased to $(686) thousand in 2025 from $(582) thousand in 2024.
• High research and development investment ($623 thousand for the quarter) primarily for SpinDx development contributed to the current period loss.
• Cash and cash equivalents decreased by $247,996 in the first six months of 2025.

Risks

• The current pace of SpinDx development may require additional financing to complete.
• Forward-looking statements involve substantial risks and uncertainties that may cause actual results to differ materially from those indicated.

Future Outlook

The company expects sales of newer L-series devices to be incremental to FC-series devices. The primary strategic focus is on leveraging the SpinDx technology platform to develop devices and tests for rapid, quantitative detection of drugs of abuse. The initial product release for SpinDx, a device for delta-9-THC detection from oral fluid, is projected for commercial launch in early 2026. Following this, more SpinDx offerings are expected, including expanded drug panels and samples collected from blood and breath. The company also anticipates accelerating the development of a roadside marijuana breathalyzer system by combining the LX9 breathalyzer with the THC SpinDx detection unit.

Management Comments

• "We believe our core alcohol detection product line-up is strong."
• "We expect that sales of our newer L-series devices will be incremental to FC-series devices rather than displacing FC sales."
• "We believe our most important goal and best opportunity remains the convergence of the global need for rapid detection of drugs of abuse with Lifeloc’s proven capability to build easy-to-use portable testing equipment."
• "We are therefore focusing our research and development efforts on leveraging the SpinDx technology platform, sometimes referred to as Lab on a Disk, to develop a series of devices and tests that can be used at roadside and in emergency rooms, forensic labs and workplace test sites to achieve a rapid and quantitative measure for a panel of drugs of abuse."
• "We are pleased to build customer engagement as the product gets closer to launch."
• "We have identified rapid drug testing as our biggest growth opportunity, and we believe that SpinDx will play an important role in addressing this unmet market need." Dr. Wayne Willkomm, President and CEO.

Industry Context

The company operates within the breath alcohol and drug testing device industry, which is experiencing a growing global need for rapid and quantitative drug detection solutions across various sectors, including law enforcement, healthcare, and workplace safety. The strategic focus on the SpinDx platform aligns with this market demand. The company's transition to the OTCID market tier reflects the evolving regulatory and market access landscape for publicly traded companies, aiming to enhance market confidence and liquidity.

Comparison to Industry Standards

• L-series devices have been certified to meet the requirements of modern registration standards, such as SAIs (Standards Australia International) latest AS 3547:2019 standards for Breath Alcohol Detectors.
• SpinDx measurement technology has been validated in the laboratory against the definitive standard liquid chromatography-mass spectroscopy (LCMS) measurement utilizing human samples, with test results on real-world human saliva tests at a limit of detection of approximately 10 ng/ml.
• The Easycal automated calibration station is highlighted as the only automated calibration available for portable breath alcohol testers, suggesting a unique competitive advantage in this specific product category.

Corporate Governance

Stakeholder Impact

• Shareholders may experience increased net losses and potential dilution from future capital raises, but could benefit from increased market confidence and liquidity due to the OTCID listing and the long-term growth potential of the SpinDx platform.
• Customers will benefit from the continued evolution and certification of existing alcohol detection products and the anticipated launch of new, innovative drug testing devices via the SpinDx platform.
• Employees, particularly in R&D, are engaged in significant development efforts for the SpinDx platform, indicating continued investment in innovation and future growth areas.

Next Steps

• Continue to evolve the capability and add certifications for L-series units to create more value and gain market share.
• Continue to improve SpinDx technology's robustness, speed, and convenience of operation.
• Update SpinDx disk design to accomplish the entire analysis on the disk and optimize drug assays.
• Begin beta testing of the SpinDx oral fluid testing system utilizing delta-9-THC only tests with a prototype reader, and finalize test logistics.
• Projected commercial launch of the first SpinDx application (delta-9-THC oral fluid device) in early 2026.
• Following initial commercialization, expect more SpinDx offerings, including expanded drug panels and samples collected from blood and breath.
• Accelerate development of combining the LX9 breathalyzer with the THC SpinDx detection unit to produce a roadside marijuana breathalyzer system.
• SpinDx prototypes are starting to travel to trade shows for key customer demonstrations.

Key Dates

Recommendation

While current financial results show declining revenue and increased losses, and there is a stated need for additional financing, the company is making significant strategic investments in the SpinDx drug testing platform, which addresses a large unmet market need. The progress in SpinDx development and its potential for future growth, coupled with the stable performance of the core alcohol detection business and the OTCID listing, suggest a 'hold' position. Investors should monitor the progress of SpinDx commercialization and details of any future capital raises.

Keywords

Lifeloc Technologies, LCTC, breath alcohol testing, drug testing, SpinDx, portable testing equipment, delta-9-THC, fentanyl, cocaine, amphetamine, methamphetamine, morphine, MDMA, benzodiazepines, oral fluid testing, roadside breathalyzer, Q2 2025 results, financial performance, OTCID